What Is Hepatitis C?

Hepatitis C (once called non-A, non-B hepatitis) is a liver disease caused by a recently identified blood-borne virus. Discovered in 1989, this strain of acute viral hepatitis causes approximately 25,000 new infections in the US each year.

Recovery from this infection is rare - about 75 percent of infected persons become chronic carriers of the virus. Approximately 25 percent of people infected with hepatitis C virus will become sick with jaundice or other symptoms of hepatitis. Seventy-five percent of these individuals may go on to develop chronic liver disease.

Chronic liver disease due to hepatitis C causes between 8,000 and 10,000 deaths and is the leading indication for liver transplantation each year in the United States. By the year 2010, the number of deaths from hepatitis C is expected to rise to 38,000 each year.

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.